SCHEMBL4751002

SCHEMBL4751002

Cc1cccc(CCCOCCOC(=O)N2CCN(Cc3ccccc3)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
GRM5 P41594 1/20 0.46
CHRM4 P08173 5/20 0.45
MCHR1 Q99705 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
OPRM1 P35372 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
TSHR P16473 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALOX15 P16050 1/20 0.43
USP2 O75604 1/20 0.43
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753160 0.95 ALDH1A1 (0.50) ALDH1A1KDM4ECYP1A2CYP3A4GRM5
SCHEMBL4751028 0.90 ALDH1A1 (0.45) ALDH1A1KDM4ETSHRKMT2A
SCHEMBL4750996 0.84 ALDH1A1 (0.45) ALDH1A1KDM4ECYP1A2SMN1; SMN2ALOX15
SCHEMBL4753147 0.82 ALDH1A1 (0.45) ALDH1A1KDM4EHTR7KMT2AL3MBTL1
SCHEMBL4750797 0.82 GRM5 (0.41) ALDH1A1KDM4ECYP1A2CYP3A4GRM5
SCHEMBL4750772 0.82 ALDH1A1 (0.45) ALDH1A1KDM4EUSP2KMT2AL3MBTL1
SCHEMBL4750792 0.78 POLB (0.52) ALDH1A1KDM4ECYP1A2TSHRKMT2A
SCHEMBL4753111 0.78 ALDH1A1 (0.42) ALDH1A1KDM4EKMT2AL3MBTL1
SCHEMBL4751026 0.78 MAPT (0.41) ALDH1A1KDM4ECYP1A2TSHRSMN1; SMN2
SCHEMBL4753349 0.77 ALDH1A1 (0.47) ALDH1A1KDM4EHTR7KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008147864-A2 METHODS OF USING PIPERAZINE COMPOUNDS IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-12-04 WO disclosed